Crossover Assignment Satisfaction
1. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943–1951. doi: 10.1007/s00198-009-1134-4.[PubMed][Cross Ref]
2. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–1501. doi: 10.4065/82.12.1493.[PubMed][Cross Ref]
3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022. doi: 10.4065/81.8.1013.[PubMed][Cross Ref]
4. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86:202–210. doi: 10.1007/s00223-009-9329-4.[PubMed][Cross Ref]
5. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008. doi: 10.1007/s00198-004-1652-z.[PubMed][Cross Ref]
6. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922–928. doi: 10.1016/j.bone.2005.10.022.[PubMed][Cross Ref]
7. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–740.[PubMed]
8. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care. 2005;43:1203–1207. doi: 10.1097/01.mlr.0000185733.30697.f6.[PubMed][Cross Ref]
9. Byer B, Myers LB. Psychological correlates of adherence to medication in asthma. Psychol Health Med. 2000;5:389–393. doi: 10.1080/713690213.[Cross Ref]
10. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38–44. doi: 10.1258/095646204322637245.[PubMed][Cross Ref]
11. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010;21:837–846. doi: 10.1007/s00198-009-1023-x.[PubMed][Cross Ref]
12. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205–210. doi: 10.1093/annonc/mdj044.[PubMed][Cross Ref]
13. Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord. 2006;90:217–221. doi: 10.1016/j.jad.2005.08.018.[PubMed][Cross Ref]
14. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38:S2–S6. doi: 10.1016/j.bone.2006.01.150.[PubMed][Cross Ref]
15. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5:618–625. doi: 10.1016/j.coph.2005.06.005.[PubMed][Cross Ref]
16. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–1066. doi: 10.1359/JBMR.040305.[PubMed][Cross Ref]
17. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831. doi: 10.1056/NEJMoa044459.[PubMed][Cross Ref]
18. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22:1832–1841. doi: 10.1359/jbmr.070809.[PubMed][Cross Ref]
19. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–161. doi: 10.1359/jbmr.0809010.[PubMed][Cross Ref]
20. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765. doi: 10.1056/NEJMoa0809493.[PubMed][Cross Ref]
21. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725–1735 [PubMed]
22. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24. doi: 10.1080/08870449908407311.[Cross Ref]
23. Gold DT, Horne R, Hill C, Borenstein J, Varon S, Macarios D. Development, reliability, and validity of a new preference satisfaction questionnaire (PSQ) J Bone Miner Res. 2008;23:S210–S211.
24. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf. 2010;19:1233–1240. doi: 10.1002/pds.2048.[PMC free article][PubMed][Cross Ref]
25. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004;20:1291–1300. doi: 10.1185/030079904125004475.[PubMed][Cross Ref]
26. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–2938. doi: 10.1001/jama.296.24.2927.[PubMed][Cross Ref]
27. Gallagher AM, Rietbrock S, Olson M, Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569–1575. doi: 10.1359/jbmr.080510.[PubMed][Cross Ref]
28. Ström O, Borgström F, Kanis JA, Jönsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009;20:23–34. doi: 10.1007/s00198-008-0644-9.[PubMed][Cross Ref]
29. Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967–982. doi: 10.1007/s00198-010-1424-x.[PMC free article][PubMed][Cross Ref]
DevFactory Technical Product Manager - $100k
Are you in a technical role now and have a vision for how things SHOULD be built but lack the influence to change it?
Some of the best Technical Product Managers come from strong technical leaders who decide to make the jump from implementing a product to defining a product. DevFactory is especially suited for you, as we are a By Developers, for Developers focused company.
Are you a great Technical Product Manager looking for the next big thing?
DevFactory is one of the most exciting companies you could imagine for Technical Product Managers. Hard problems, revolutionary technology, and a great team.
One of the best Technical Product Management jobs. Period.
Here are a just a few reasons why:
By Developers for Developers: As a Technical Product Manager, you know software development. Youve very likely have had a significant portion of your career in software development. All those times you thought to yourself I would absolutely have created this tool way better... in this role you can.
Define products you would love to use.
Iteration, Improvement focused culture: We have a culture that not only enables your success, but strives to always think what better looks like. We view this iterative improvement as a necessity not only from an individual perspective, but as a team. You will be an integral part to improving not only products, but how we deliver products.
Career Focus: Candidates have a clear career path to increased compensation and responsibility. As your skills and competencies grow, your scope and area of impact will grow as well.
Customer Focus: At DevFactory, how our Customers will actually use our product (the use case), is the primary driver behind every specification. We believe that by centralizing the Use Case, we can focus on what makes our products great for our customers, and unique in the marketplace.
Learn and Use Disruptive Tech: Every day you hear about how some new company is applying disruptive technology to a stagnant industry. Wouldnt you like to be working for those innovative companies working on those new industry changing approaches? At Devfactory, this is your chance to be a part of that and both learn and apply these disruptive technologies (such as AI, Machine Learning, Big Data analysis, NLP, PaaS Cloud services) from Open Source, AWS, Google, and others.
Work/Life Balance: DevFactory is a fully remote company, with every role being a fully remote role. Simply put, DevFactory provides you with a unique work/life flexibility and the opportunity to work with a global team of top performers in their field.
A bit about DevFactory
The DevFactory culture is rooted in a deep appreciation of software and software development combined with an intense desire to use metrics and objective data to make software development better. We are inspired by the industrial manufacturing revolution that happened over 100 years ago. Jobs were loosely defined, not measured, not specialized, not automated, and the result was terrible quality and productivity. Today manufacturing is dominated by scientific measurement, automation, specialization, and well defined processes - making it very high quality and 100x more productive. We see the same opportunity in large scale software development.
We build systems that help make software and software dev teams better. We measure the quality of code, tests, builds, and architectures at a deep level; finding valuable insights not just surface level coding violations. We mine the history of source control systems to help dev teams find their buggiest parts of code, most productive developers, riskiest classes, etc. We build active systems that evaluate code on every commit and help our customers prevent their software quality from slowly eroding and accumulating expensive technical debt.
If making software better and development teams more productive is something you are passionate about, youll be inspired at DevFactory.
DevFactory is actively hiring candidates for this position through the CrossOver marketplace on Crossover.com. Crossover is one of the most legitimate companies offering high-paying jobs that are 100% remote, work from home. You never have to fight traffic to the office again and you have the freedom to choose when and where you put in your 40 hours to be most effective each week.
Responsibilities of the Role
As a Technical Product Manager, your core responsibility is to take the big ideas from Product Management Leadership and figure out how to break it down into meaningful bite-size chunks for Engineering. Were relying on you to take that large complex release, figure out how it should be functionally broken down, and then defining that very clearly for the development team to go implement. Youll be using your deep technical background to identify the key decisions that need to be made (sometimes the hardest part!), finding the best answer to those questions and then defining both how the product will be implemented, and what you want to see to know that it was implemented correctly.
At DevFactory were Agile. We have 1-2 week sprints that focus on a clear milestone of work in the greater release. As a Technical Product Manager, your primary responsibility is to take the large release level ideas and break it into clear Milestone specifications that the development team can actually build. As you will be the owner for the area, you will be ultimately responsible for reviewing what the engineering team has actually built and making the final call on if it meets exactly what you specified or needs additional work.